MindMaze secures CHF 8 million to expand its neurotherapeutics platform

MindMaze Therapeutics announced a CHF 8 million strategic equity financing from Neuro.io Group, funding the expansion of its U.S. commercial operations and opening the door to a potential combination of neurotherapeutics and artificial intelligence.

MindMaze Therapeutics, a Geneva-based company specializing in scalable precision neurotherapeutics, entered into a definitive agreement for a CHF 8 million equity financing with Neuro.io Group. Through the transaction, Neuro.io will acquire a strategic equity position in the company.

The proceeds will support MindMaze Therapeutics’ commercial priorities, including the expansion of its footprint in the United States and the broader deployment of its neurotherapeutics solutions. The financing is structured in two tranches of treasury share purchases and mandatory convertible loan notes, which are expected to convert into close to 30 million ordinary shares over the following twelve months, strengthening the company’s balance sheet as it scales operations.

Alongside the financing, the two parties signed a letter of intent to explore a range of strategic opportunities, including a potential business combination. The discussions are expected to focus on pairing MindMaze Therapeutics’ clinically validated neurotherapeutics platform with Neuro.io’s healthcare-focused AI and computing capabilities to advance AI-enabled interventions targeting neurological disorders.